Antidepressant drugs, new

Reserpine and the MAO inhibitors thus afforded the medical breakthrough to the chemical treatment of mental illness and established a rational basis for synthetic drug design of antipsychotic and antidepressant drugs. New types of biochemical and pharmacological screening procedures were developed as a result of Brodie s work, and the 1960 s were to become the era of the biogenic amines. 

Simon G, Wagner E, VonKorff M (1995b). Cost-effectiveness comparisons using Real World randomised trials the case of new antidepressant drugs. J Clin Epidemiol4, 363-73. 

Moore s idea of analysing the data that had been sent to the FDA seemed brilliant, and I proposed that we work on it together. So we began. Moore wrote to the FDA invoking the Freedom of Information Act and requested the medical and statistical reviews of every placebo-controlled clinical trial for the treatment of depression by what, at that time, were the six most widely used new-generation antidepressant drugs Prozac, Seroxat (Paxil in... 

Steimer, W., et al., "Pharmacogenetics A New Diagnostic Tool in the Management of Antidepressive Drug Therapy," Clin. Chim. Acta, 308, 33-41 (2001). 

Tariot PN, Cohen RM, Welkowitz JA, et al Multiple-dose arecohne infusions in Alzheimer s disease. Arch Gen Psychiatry 45 901-905, 1988 Taylor AE, Saint-Cyr JA, Lang AE Frontal lobe dysfunction in Parkinson s disease the cortical focus of neostriatal outflow. Brain 109 845-883, 1986 Taylor DP, Smith DW, Hyslop DK, et al Receptor binding and atypical antidepressant drug discovery, in Receptor Binding in Drug Research. Edited by O Brien RA. New York, Marcel Dekker, 1986, pp 151-165 Tejedor-Real P, Mico JA, Maldonado R, et al Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol Psychiatry 34 100-107, 1993... 

More recent developments in psychopharmacology that are of interest include atypical antipsychotic drugs, new antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), and drugs for the treatment of Alzheimer s disease. 

Curran, H.V. Antidepressant drugs, cognitive function and human performance. In Smith, A, Jones, D. (eds) Hmdhook of Human Performance, Vol. 2. Academic Press, New York, 1992a, pp. 319-336. 

Klerman. G.L., Weissman, M.M., Prusoff. B.A. RDC endogenous depression as a predictor of response to antidepressant drugs and psychotherapy. In Costa, E., Racagni, G. (eds) Typical and Atypical Antidepressants Clinical Practice. Raven, New York, 1982, pp. 165-174. 

Shorter, Edward. How Prozac Slew Freud. American Heritage 49, no. 5 (September 1998) 42-44. In this brief history of psychiatry, the author examines remarkable changes in the treatment of mental illness. Rather than treating problems with drawn-out therapy, psychiatrists most often end a patient visit with a prescription to antidepressant drugs like Prozac. The article illustrates the wide-ranging impact over the last several decades of new prescription drugs. 

Ardid, D. and Guilbaud, G. Antinociceptive effects of acute and chronic injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats, Pain 1992, 49, 279-287. 

In this chapter, we will review pharmacological concepts underlying the use of several classes of antidepressant drugs, including the classical monoamine oxidase (MAO) inhibitors, the classical tricyclic antidepressants, the popular serotonin selective reuptake inhibitors (SSRIs), and the new selective noradrenergic reuptake... 

Electroconvulsive therapy is especially useful when rapid onset of clinical effect is desired and when patients are refractory to a number of antidepressant drugs. It is also very helpful in psychotic and bipolar depression and in postpartum psychosis. If the mechanism of the therapeutic action of ECT could be unraveled, it might lead to a new antidepressant drug capable of rapid onset of antidepressant effects or with special value for refractory patients. Until then, ECT will remain a valuable member of the therapeutic armamentarium for depression. 

Stahl s Essential Psychopharmacology has established itself as the preeminent source of education and information in its field. This much expanded second edition enlists advances in neurobiology and recent clinical developments to explain with renewed clarity the concepts underlying drug treatment of psychiatric disorders. New neurotransmitter systems, new theories of schizophrenia, clinical advances in antipsychotic and antidepressant therapy, new coverage of attention deficit disorder, sleep disorders, and drug abuse, and a new chapter on sex-specific and sexual function-related psychopharmacology—these are all features of this edition. 

Scientists were looking for drugs to treat different medical problems when their observations almost accidentally led them to the study of depression and its treatment. Many scientists continued in this new direction to the discovery of the current three classifications of antidepressant drugs used today monamine oxidase... 

While the amine hypothesis is undoubtedly too simplistic, it has provided the major experimental models for the discovery of new antidepressant drugs. As a result, all the currently available antidepressant drugs—except bupropion—are classified as having their primary actions on the metabolism, reuptake, or selective receptor antagonism of serotonin, norepinephrine, or both. 

Leonard, B. E. The potential contribution of sigma receptors to the action of antidepressant drugs. In Antidepressants - New Pharmacological Strategies, Skolnick, P. (Ed.). Totowa, NJ Humana Press, 1997, pp. 159-172. 

For example, soon after the new arthritis drug Celebrex entered the market, the FDA received 53 reports of dispensing errors that occurred when it was mistaken for the antiseizure drug Cerebyx or the antidepressant drug Celexa. Other commonly... 

The selective serotonin-reuptake inhibitors (SSRI) are a new group of chemically unique antidepressant drugs that specifically inhibit serotonin reuptake (see Figure 12.3). This contrasts with the tricyclic antidepressants that nonselectively inhibit the uptake of norepinephrine, and serotonin, and block muscarinic, H histaminic and a -adrenergic receptors. Compared with tricyclic antidepressants, the SSRIs cause fewer anticholinergic effects and lower cardiotoxicity. However, the newer serotonin reuptake inhibitors should be used cautiously until their long-term effects have been evaluated. 

---